Cargando…

In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients

BACKGROUND: We sought to determine the predictive value of in situ mRNA measurement compared to traditional methods on a cohort of trastuzumab-treated metastatic breast cancer patients. METHODS: A tissue microarray composed of 149, classified as HER2-positive, metastatic breast cancers treated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vassilakopoulou, Maria, Togun, Taiwo, Dafni, Urania, Cheng, Huan, Bordeaux, Jennifer, Neumeister, Veronique M., Bobos, Mattheos, Pentheroudakis, George, Skarlos, Dimosthenis V., Pectasides, Dimitrios, Kotoula, Vassiliki, Fountzilas, George, Rimm, David L., Psyrri, Amanda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072595/ https://www.ncbi.nlm.nih.gov/pubmed/24968015 http://dx.doi.org/10.1371/journal.pone.0099131

Ejemplares similares

Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
por: Fountzilas, George, et al.
Publicado: (2012)

Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial
por: Fountzilas, George, et al.
Publicado: (2013)

alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies
por: Koletsa, Triantafyllia, et al.
Publicado: (2014)

Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study
por: Koutras, Angelos, et al.
Publicado: (2018)

MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer
por: Gogas, Helen, et al.
Publicado: (2016)

Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel
por: Fountzilas, George, et al.
Publicado: (2012)

Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Based Regimens
por: Kourea, Helen P., et al.
Publicado: (2022)

Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer
por: Fountzilas, Elena, et al.
Publicado: (2019)

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting
por: Fountzilas, George, et al.
Publicado: (2016)

Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials
por: Kotoula, Vassiliki, et al.
Publicado: (2015)

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
por: Fountzilas, George, et al.
Publicado: (2012)

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials
por: Fountzilas, George, et al.
Publicado: (2013)

Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab
por: Economopoulou, Panagiota, et al.
Publicado: (2019)

Adjusting Breast Cancer Patient Prognosis with Non-HER2-Gene Patterns on Chromosome 17
por: Kotoula, Vassiliki, et al.
Publicado: (2014)

Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab
por: Mountzios, G, et al.
Publicado: (2019)

MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer
por: Fountzilas, George, et al.
Publicado: (2009)

Protein expression patterns of cell cycle regulators in operable breast cancer
por: Zagouri, Flora, et al.
Publicado: (2017)

Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study
por: Koutras, Angelos, et al.
Publicado: (2015)

Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
por: Gogas, Helen, et al.
Publicado: (2010)

Prognostic Significance of ESR1 Gene Amplification, mRNA/Protein Expression and Functional Profiles in High-Risk Early Breast Cancer: A Translational Study of the Hellenic Cooperative Oncology Group (HeCOG)
por: Pentheroudakis, George, et al.
Publicado: (2013)

Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy
por: Kostopoulos, Ioannis, et al.
Publicado: (2009)

Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer
por: Fountzilas, Elena, et al.
Publicado: (2018)

Comparison of HER2 and Phospho-HER2 Expression between Biopsy and Resected Breast Cancer Specimens Using a Quantitative Assessment Method
por: Bai, Yalai, et al.
Publicado: (2013)

EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial
por: Cheng, H, et al.
Publicado: (2014)

Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes
por: Kotoula, Vassiliki, et al.
Publicado: (2016)

Markers of Epithelial to Mesenchymal Transition in Association with Survival in Head and Neck Squamous Cell Carcinoma (HNSCC)
por: Pectasides, Eirini, et al.
Publicado: (2014)

Identification and Validation of a Multigene Predictor of Recurrence in Primary Laryngeal Cancer
por: Fountzilas, Elena, et al.
Publicado: (2013)

Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study
por: Razis, Evangelia, et al.
Publicado: (2008)

Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
por: Pectasides, Dimitrios, et al.
Publicado: (2015)

Genotyping data of routinely processed matched primary/metastatic tumor samples
por: Kotoula, Vassiliki, et al.
Publicado: (2020)

Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study
por: Murray, Samuel, et al.
Publicado: (2010)

Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer
por: Polychronidou, Genovefa, et al.
Publicado: (2018)

Treating EGFR-Mutated Oncogene-Addicted Advanced Non–Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities
por: Fountzilas, Elena, et al.
Publicado: (2018)

Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG)
por: Zarkavelis, George, et al.
Publicado: (2019)

A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)
por: Pentheroudakis, George, et al.
Publicado: (2014)

Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer
por: Murray, Samuel, et al.
Publicado: (2012)

Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas
por: Kountourakis, Panteleimon, et al.
Publicado: (2006)

Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time Diagnostics
por: Kotoula, Vassiliki, et al.
Publicado: (2009)

Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative
por: Fountzilas, Elena, et al.
Publicado: (2020)

Immune Response Gene Expression in Colorectal Cancer Carries Distinct Prognostic Implications According to Tissue, Stage and Site: A Prospective Retrospective Translational Study in the Context of a Hellenic Cooperative Oncology Group Randomised Trial
por: Pentheroudakis, George, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fgdtq7qkpnjjp18n2qsq6fqi2n